212 related articles for article (PubMed ID: 26744322)
1. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
Kodali S; Bathini V; Rava P; Tipirneni E
J Gastrointest Cancer; 2017 Mar; 48(1):66-69. PubMed ID: 26744322
[No Abstract] [Full Text] [Related]
2. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
Lunenburg C; Swen JJ; Guchelaar HJ; Gelderblom H
J Gastrointest Cancer; 2017 Mar; 48(1):117-118. PubMed ID: 28025815
[No Abstract] [Full Text] [Related]
3. [Dihydropyrimidine dehydrogenase deficiency causes severe adverse effects of capecitabine].
Inoue H; Sato Y; Shintani S; Tanabe H; Bamba H; Komai Y; Nakamura T; Imai T; Andou A
Nihon Shokakibyo Gakkai Zasshi; 2018; 115(3):290-298. PubMed ID: 29526981
[TBL] [Abstract][Full Text] [Related]
4. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
5. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine Toxicity and Dihydropyrimidine Dehydrogenase Deficiency.
Tariq Z; Mudge R; Phillips S
Am J Ther; 2018; 25(6):e742-e743. PubMed ID: 29889674
[No Abstract] [Full Text] [Related]
7. Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency.
Bermejo-Pérez MJ; Galeote-Miguel AM; Rodelo-Haad LE; Alés-Díaz I; Durán-Ogalla G; Benavides-Orgaz M
Chemotherapy; 2014; 60(5-6):353-5. PubMed ID: 26330092
[TBL] [Abstract][Full Text] [Related]
8. Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review.
Hagiwara Y; Yamamoto Y; Inagaki Y; Tomisaki R; Tsuji M; Fukuda S; Fukuda S; Onoda T; Suzuki H; Niisato Y; Tange Y; Ikeda N; Yamada K; Kobayashi M; Akutsu D; Yamada T; Moriwaki T; Narasaka T; Suzuki H; Tsuchiya K
Intern Med; 2022 Aug; 61(16):2449-2455. PubMed ID: 35110482
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
10. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
Gbeto CC; Quaranta S; Mari R; Fanciullino R; Roche C; Nahon S; Solas C; Ouafik L; Lacarelle B; Allegre T; Ciccolini J
Pharmacogenomics; 2019 Aug; 20(13):931-938. PubMed ID: 31486738
[TBL] [Abstract][Full Text] [Related]
11. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
[TBL] [Abstract][Full Text] [Related]
12. Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
Garcia RAG; Saydoff JA; Bamat MK; von Borstel RW
Toxicol Appl Pharmacol; 2018 Aug; 353():67-73. PubMed ID: 29908244
[TBL] [Abstract][Full Text] [Related]
13. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
Zurayk M; Keung YK; Yu D; Hu EH
J Oncol Pharm Pract; 2019 Jan; 25(1):234-238. PubMed ID: 28950804
[TBL] [Abstract][Full Text] [Related]
14. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
[TBL] [Abstract][Full Text] [Related]
15. Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare
van Kuilenburg ABP; Pleunis-van Empel MCH; Brouwer RB; Sijben AEJ; Knapen DG; Oude Munnink TH; van Zanden JJ; Janssens-Puister J; Dobritzsch D; Meinsma R; Meijer-Jansen J; van Dooren SJM; Vijzelaar R; Pop A; Salomons GS; Maring JG; Niezen-Koning KE
JCO Precis Oncol; 2024 May; 8():e2300599. PubMed ID: 38709992
[TBL] [Abstract][Full Text] [Related]
16. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Yang CG; Ciccolini J; Blesius A; Dahan L; Bagarry-Liegey D; Brunet C; Varoquaux A; Frances N; Marouani H; Giovanni A; Ferri-Dessens RM; Chefrour M; Favre R; Duffaud F; Seitz JF; Zanaret M; Lacarelle B; Mercier C
Cancer Chemother Pharmacol; 2011 Jan; 67(1):49-56. PubMed ID: 20204365
[TBL] [Abstract][Full Text] [Related]
17. [Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection].
Nagai K; Okuda Y; Ohara Y; Yamamoto M
Gan To Kagaku Ryoho; 2015 Jan; 42(1):127-9. PubMed ID: 25596695
[TBL] [Abstract][Full Text] [Related]
18. A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
Obi EE; McDonald A; Kemp E
Cutan Ocul Toxicol; 2011 Jun; 30(2):157-9. PubMed ID: 21077799
[TBL] [Abstract][Full Text] [Related]
19. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Saif MW; Elfiky A; Diasio R
Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792
[TBL] [Abstract][Full Text] [Related]
20. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
Magnani E; Farnetti E; Nicoli D; Casali B; Savoldi L; Focaccetti C; Boni C; Albini A; Banzi M
Intern Emerg Med; 2013 Aug; 8(5):417-23. PubMed ID: 23585145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
